[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "(857) 330-4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 59, "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 4.4, "open": 4.38, "dayLow": 4.38, "dayHigh": 4.4804, "regularMarketPreviousClose": 4.4, "regularMarketOpen": 4.38, "regularMarketDayLow": 4.38, "regularMarketDayHigh": 4.4804, "beta": 1.548, "forwardPE": -2.8343947, "volume": 617483, "regularMarketVolume": 617483, "averageVolume": 572874, "averageVolume10days": 330580, "averageDailyVolume10Day": 330580, "bid": 4.43, "ask": 4.5, "bidSize": 200, "askSize": 100, "marketCap": 275256960, "fiftyTwoWeekLow": 2.689, "fiftyTwoWeekHigh": 7.795, "fiftyDayAverage": 4.6464, "twoHundredDayAverage": 4.615, "currency": "USD", "enterpriseValue": 155739008, "floatShares": 37908149, "sharesOutstanding": 61855500, "sharesShort": 2692344, "sharesShortPriorMonth": 3153357, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0435, "heldPercentInsiders": 0.00519, "heldPercentInstitutions": 0.92743, "shortRatio": 5.16, "shortPercentOfFloat": 0.047199998, "impliedSharesOutstanding": 61855500, "bookValue": 1.922, "priceToBook": 2.3152964, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -77112000, "trailingEps": -1.35, "forwardEps": -1.57, "pegRatio": -0.21, "enterpriseToEbitda": -1.894, "52WeekChange": -0.17592591, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INZY", "underlyingSymbol": "INZY", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f627b06e-ce15-3126-896c-1db8a4222086", "messageBoardId": "finmb_568596329", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.45, "targetHighPrice": 40.0, "targetLowPrice": 14.0, "targetMeanPrice": 19.43, "targetMedianPrice": 15.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 166152992, "totalCashPerShare": 2.686, "ebitda": -82213000, "totalDebt": 46635000, "quickRatio": 13.393, "currentRatio": 14.052, "debtToEquity": 39.243, "returnOnAssets": -0.32558, "returnOnEquity": -0.69413, "freeCashflow": -52528376, "operatingCashflow": -77436000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]